WFL-reactive glycans as a part of clinically useful glycoproteins (including but not limited to FDA-approved oncomarkers, such as PSA) might be used in different platforms for PCa detection, such as label or label-free formats of different biosensors (e.g., two-step surface plasmon field-enhanced fluorescence spectrometry (SPFS)-based WFA lectin-anti-PSA antibody immunoassay) [140], lectin microarray [141,142] or lectin-based histochemistry [143]; the latter does not apply to liquid biopsy approaches. The gene discussed is KLK3; the disease is posterior cortical atrophy.